Abstract 2453
Background
Recent development in cancer care challenges the earlier and more linear care trajectory. This implies an increased need for symptom management and support. In research on intensity of care at end-of-life (EOL), there is a trend to increased utilization of health, such as re-admissions, emergency admissions and to intensive care (ICU). Previous research has investigated factors such as gender, socio-economic status, comorbidities and type of disease. Research on symptoms leading to hospitalizations reveal that more than half of symptoms were related to disease and 30% to side-effects from treatment. Some research reveals that symptom burden in hospitalized patients may be associated with hospital length of stay (LOS) and re-admissions. This study aims to analyze the relationship between Health-Related Quality of Life (HRQoL) and different aspects of health care utilization, such as; LOS, re-admissions within 30 days and unplanned care.
Methods
Survey data using the European Organization for Research and Treatment of Cancer (EORTC QLQ C30) tool on HRQoL were linked data from the Swedish Cancer Quality registries and the database for health care utilization. Patients with a complex care trajectory (in this study Gynecology, Head & Neck, Hematology and Upper GI cancer) were included. Functional scales and symptom scales from EORTC QLQ C30 were analyzed for correlations with LOS, re- admissions within 30 days and unplanned care. Independent variables are patient demographics and clinical variables such as; treatment and/or type of treatment, performance status, co-morbidities and referral to palliative care.
Results
In total, 1872 patients responded to the survey (response rate 64 %), 41 % men and 59 % women (mean age 67 years). The number of patients in each group are; Gynecological (n 598), Hematological (n 461), Head & Neck (n 395) and Upper GI cancers (n 418). Analysis are currently ongoing with multivariate regression models and will be presented in the poster/oral presentation.
Conclusions
On possible correlations between different factors related to aspects of care utilization will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This investigation and study was supported by grants from the Cancer Research Foundation in Northern Sweden.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract